Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Coeptis Therapeutics Inc
COEPCoeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. It is developing cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, natural killer cell therapy technology. The company is also developing a multi-antigen CAR T technology licensed from the University of Pittsburgh, and the GEAR cell therapy and companion diagnostic platforms, which are developing with VyGen-Bio and medical researchers at the Karolinska Institute. Its Product Pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania. Address: 105 Bradford Road, Wexford, PA, United States, 15090
Analytics
Precio Objetivo de WallStreet
3.00 USDRelación P/E
–Rentabilidad por dividendo
–Cifras clave COEP
- Margen de Beneficio
- Ingresos Totales
- Beneficio Bruto
- Ingresos Netos
Análisis de dividendos COEP
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y>5 - expected 5-9 dividend yield on cost over 10Y<5 - expected <5 dividend yield on cost over 10YMaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout COEP
- Relación de Pago
- Dividends
- Rentabilidad por dividendo
Valoración de la acción COEP
- Relación Precio/Ventas
- Relación PE
- Relación Precio/Valor en Libros
- Relación Corriente
- Relación de Deuda
Finanzas COEP
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 31.12.2017 | 31.12.2018 | 31.12.2019 | 31.12.2020 | 31.12.2021 | 31.12.2022 | 31.12.2023 | Dinámica | |
Ingresos Totales | 411 822 GBX | 372 866 GBX | 463 841 GBX | 1 790 436 GBX | 2 568 167 GBX | 637 752 GBX | 1 202 616 GBX | ||
Ingresos Operativos | -5 774 241 GBX | -16 526 904 GBX | -14 023 664 GBX | -15 866 119 GBX | -17 514 643 GBX | -18 757 220 GBX | -14 800 468 GBX | ||
Ingresos Netos - (CF) | -6 432 012 GBX | -16 650 884 GBX | -14 159 624 GBX | -16 911 828 GBX | -82 790 810 GBX | -20 777 682 GBX | -14 407 583 GBX | ||
BPA Básico Normalizado | - | - | - | - | -0.01 GBX | - | - | ||
Dividendo por Acción | 0.00 GBX | 0.00 GBX | 0.00 GBX | 0.00 GBX | 0.00 GBX | 0.00 GBX | 0.00 GBX | ||
Relación de Pago | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | ||
Total de Activos | 5 606 281 GBX | 4 496 573 GBX | 2 912 048 GBX | 2 634 176 GBX | 34 129 585 GBX | 16 563 928 GBX | 5 732 193 GBX | ||
Total de Pasivos | 12 152 302 GBX | 22 389 183 GBX | 28 977 174 GBX | 36 451 881 GBX | 4 481 578 GBX | 4 923 467 GBX | 3 647 886 GBX | ||
Relación de Deuda | 2.17 | 4.98 | 9.95 | 13.84 | 0.13 | 0.30 | 0.64 | ||
Total de Activos Corrientes | 2 820 068 GBX | 2 290 296 GBX | 1 009 690 GBX | 1 746 456 GBX | 33 493 766 GBX | 15 124 329 GBX | 4 748 551 GBX | ||
Total de Pasivos Corrientes | 12 150 292 GBX | 22 389 183 GBX | 28 661 274 GBX | 35 774 090 GBX | 3 920 733 GBX | 3 905 738 GBX | 3 488 892 GBX | ||
Relación Corriente | 0.23 | 0.10 | 0.04 | 0.05 | 8.54 | 3.87 | 1.36 | ||
Relación Rápida | 0.18 | 0.08 | 0.02 | 0.04 | 8.27 | 3.54 | 1.06 | ||
Rentabilidad sobre Activos | -114.73 % | -370.30 % | -486.24 % | -642.02 % | -242.58 % | -125.44 % | -251.35 % | ||
Cobertura de Intereses FFO | -6.95 | -130.22 | -77.16 | -32.14 | -14.47 | -644.75 | -378.63 | ||
Relación P/E - P/E (LTM) | - | - | - | - | -55.84 | -178.89 | -117.83 | ||
Rentabilidad por dividendo (LTM) | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | ||
Rendimiento de Recompra (LTM) | - | - | - | - | 59.07 % | -144.34 % | -1.30 % |